Czech and Slovak Ophthalmology 544 Original article Photodynamic Therapy with Verteporfin in Treatment of Myopic Neovascular Choroideal Membranes Vysloužilová Daniela https://orcid.org/0009-0008-0195-2456 Kolář Petr https://orcid.org/0000-0003-3709-4648 Matušková Veronika https://orcid.org/0000-0002-3308-463X 14 8 2012 4 1

The aim of this study was to evaluate efficiency and long-term stabilization effect in patients with classic type of myopic choroidal neovascular membrane (CNV), treated with photodynamic therapy (PDT) with verteporfin (Visudyne – Novartis AG, Basel, Switzerland). We have verified the efficiency of photodynamic therapy with verteporfin in group of 51 eyes (17 men, 34 women), mean age 49,5 years with subfoveal localized predominantly classic neovascular membranes in pathologic myopia. The average follow up period was 23,7 months (± 2,3 month). Patients underwent during follow-up period 1 to 3 sessions of photodynamic therapy (PDT average number 1,25 sessions). The average best corrected visual acuity (BCVA) before treatment was 0,302 (0,65 logMAR) and the average BCVA at the end of follow up was 0,356 (0,46 log MAR). The improvement of best corrected visual acuity up to 5 letters on ETDRS (Early Treatment Diabetic Retinopathy Study) charts was observed in 23% of patients at the end of follow up.

 photodynamic therapy choroideal neovascularisation pathologic myopia References Alliston, BA, Protchard, PH, Levy, JG.: Evidence for low-density lipoprotein receptor-mediated uptake of benzo- porphyrin derivate. Br J Cancer, 1994; 69: 833–839. Bandello F, Lanzetta P, Battaglia Pa- rodi M, Ranam Poginuz Z, Saviano S, Ravalico G.: Photodynamic therapy of subfoveolar recurrences after laser photocoagulation of extrafoveolar cho- rioidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Oph- thalmol, 2003; 241: 567–570. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al.: Verteporfin therapy in subfoveal choroidal neovascu- larisation in pathologic myopia: 2-year result of a randomised clini- cal trial – VIP report no.3. Ophthal- mology 2003; 110: 667–673. Guidelines for using verteporfin (Vi- sudyne) in fotodynamic therapy for choroidal neovascularisation due to age related macular degeneration and other causes: update. Retina 2005; 25: 119–134. Hotchkiss ML, Fine SL.: Pathologic myopia and chorioideal neovascularisation. Am J Ophthalmology 1981, 91, p. 177–183. Kolář P. a kol.: Věkem podmíněná makulární degenerace. Praha, Grada, 2008. Soubrane, G., Kuhn, D., Coscas, G.: Indications for photodynamic therapy in age-related macular degeneration.J Fr Ophthalmol, 2004; 27: 79–80. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al.: Myopic choroidal neovascularisation; Ten years follow up.